Evidence map›Paper›PMID 40357899›Full record

ReviewCancer medicine2025

Bone Health Management in Men Commencing Androgen Deprivation Therapy for Prostate Cancer and Women Commencing Anti-Oestrogen Therapy for Breast Cancer.

Ian Liang, Sarah Brennan, Christian Girgis, Amy Hayden, Tania Moujaber, Sandra Turner, Anuradha Vasista, Mathis Grossmann, Peter K K Wong

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ian LiangInstitute of Rheumatology and Orthopaedics, Royal Prince Alfred Hospital, Camperdown, Sydney, New South Wales, Australia.ORCID https://orcid.org/0000-0002-5142-8707
Sarah BrennanDepartment of Endocrinology, Westmead Hospital, Westmead, New South Wales, Australia.
Christian GirgisFaculty of Medicine and Health, University of Sydney, Camperdown, New South Wales, Australia.
Amy HaydenFaculty of Medicine, Western Sydney University, Campbelltown, New South Wales, Australia.
Tania MoujaberFaculty of Medicine and Health, University of Sydney, Camperdown, New South Wales, Australia.
Sandra TurnerFaculty of Medicine and Health, University of Sydney, Camperdown, New South Wales, Australia.
Anuradha VasistaCrown Princess Mary Cancer Centre, Westmead Hospital, Westmead, New South Wales, Australia.
Mathis GrossmannDepartment of Endocrinology, Austin Health, Heidelberg, Victoria, Australia.
Peter K K WongFaculty of Medicine and Health, University of Sydney, Camperdown, New South Wales, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSurvival of patients with prostate and breast cancer, the commonest cancer in men and women, respectively, has markedly improved with advances in early diagnosis, treatment and multi-disciplinary care by the oncology and surgical community. However, the use of increasingly potent endocrine therapies may cause bone loss, resulting in secondary osteoporosis. REVIEW: This review summarises the current management of cancer treatment-induced bone loss in this group of patients at high risk of osteoporotic fractures with their attendant morbidity and mortality.

conclusionBone health is an increasingly important part of cancer survivorship. Radiation and medical oncologists, urologists, bone health experts, general practitioners, healthcare professional bodies and bone health and cancer consumer organisations should increase awareness of the potential adverse effect of endocrine therapy on bone health. While this should never delay cancer treatment, bone health should be part of routine care for men and women receiving endocrine therapy for prostate and breast cancer.

Indexed as

Androgen AntagonistsBreast NeoplasmsEstrogen AntagonistsOsteoporosisProstatic NeoplasmsBone DensityBone Density Conservation AgentsFemaleHumansMaleAndrogen AntagonistsBone Density Conservation AgentsEstrogen Antagonistsandrogen deprivation therapyaromatase inhibitorbone healthbreast cancerfracture preventionosteoporosisprostate cancer

Identifiers

PMID40357899
PMCPMC12070255

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.